Characterisation of the anti-bladder-cancer monoclonal antibody BLCA-8: identification of its antigen as a neutral glycolipid

1996 ◽  
Vol 41 (6) ◽  
pp. 348-354
Author(s):  
E. A. Kingsley ◽  
Teresa E. Carter ◽  
Kevin D. Barrow ◽  
Pamela J. Russell
Keyword(s):  
Monoclonal Antibody ◽  
Bladder Cancer ◽  
Neutral Glycolipid

Characterisation of the anti-bladder-cancer monoclonal antibody BLCA-8: identification of its antigen as a neutral glycolipid

1995 ◽  
Vol 41 (5) ◽  
pp. 317-323 ◽  
Author(s):  
E. A. Kingsley ◽  
Teresa E. Carter ◽  
Kevin D. Barrow ◽  
Pamela J. Russell
Keyword(s):  
Monoclonal Antibody ◽  
Bladder Cancer ◽  
Neutral Glycolipid

Characterisation of the anti-bladder-cancer monoclonal antibody BLCA-8: Identification of its antigen as a neutral glycolipid

1995 ◽  
Vol 41 (6) ◽  
pp. 348-354
Author(s):  
Elizabeth A. Kingsley ◽  
Teresa E. Carter ◽  
Kevin D. Barrow ◽  
Pamela J. Russell
Keyword(s):  
Monoclonal Antibody ◽  
Bladder Cancer ◽  
Neutral Glycolipid

Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients with localized muscle invasive bladder cancer: A SOGUG study.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. TPS5097-TPS5097
Author(s):  
M. Andres Cuellar ◽  
Ana Medina ◽  
Regina Girones ◽  
B.P. Valderrama ◽  
Albert Font ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Bladder Cancer ◽  
Phase Ii ◽  
External Beam Radiotherapy ◽  
Human Monoclonal Antibody ◽  
Pathological Response ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Bladder Preservation ◽  
Muscle Invasive

TPS5097 Background: Several studies have shown that long-term bladder preservation is feasible in selected patients with muscle-invasive bladder cancer, using a multimodal treatment, including transurethral resection (TUR), radiotherapy and chemotherapy. Durvalumab, a fully human monoclonal antibody against PD-L1, has shown activity in patients with advanced pretreated urothelial cancer. A preclinical study showed that the combination of radiation, anti-CTLA4 and anti-PD-L1 overcome- adaptive immune resistance and has superior activity than either therapy alone (Twyman-Saint Victor et al. Nature 2015). The purpose of the present study is to explore feasibility, toxicity and activity in terms of response and bladder preservation of the integration of TUR, immune double checkpoint inhibition with durvalumab and tremelimumab (a fully human monoclonal antibody against CTLA-4), and radiotherapy in the treatment of localized muscle-invasive. Methods: This is a multicenter prospective phase II study of multimodal therapy in patients with localized urothelial carcinoma of the bladder in clinical stages T2-4a N0 M0, ECOG 0- 1, without contraindications to immunotherapy, who either wish for bladder preservation or are ineligible for cystectomy. The primary endpoint is pathological response (≤T1) at post-treatment biopsy. A 2-stage sequential design (response rate P0=5, P1=0.7, α=0.10, β=0.20) requires at least 6 responses in the first 12 pts to expand to a second cohort of 20 patients. The treatment consists of initial TUR of the tumor, followed by durvalumab 1500 mg i.v. plus tremelimumab 75 mg i.v., every 4 weeks for 3 doses. Normofractionated external-beam radiotherapy is started 2 weeks later, at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder. Patients with pathological response will be candidates to bladder preservation, whereas those with residual muscle invasive tumor will be candidates to salvage cystectomy. At present time, prespecified activity goal for the first stage of accrual was met; second stage accrual began in December 2019. Clinical trial information: NCT03702179 .

877 ANTI-IL10-R1 MONOCLONAL ANTIBODY ENHANCES BACILLUS CALMETTE-GUERIN (BCG) INDUCED TH1 AND ANTI-BLADDER CANCER IMMUNE RESPONSES IN VITRO AND IN VIVO

2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Nathan A. Bockholt ◽  
Matthew J. Knudson ◽  
Jonathan R. Henning ◽  
Peter Weady ◽  
George J. Smith ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Bladder Cancer ◽  
Immune Responses ◽  
Bacillus Calmette Guerin

Cytokeratin Shedding in Urine as a Biological Marker for Bladder Cancer: Monoclonal Antibody-Based Evaluation

1991 ◽  
Vol 68 (3) ◽  
pp. 248-253 ◽  
Author(s):  
H. HELMY ◽  
M. N. SEDDEK ◽  
M. T. BASTA ◽  
A. SHAABAN ◽  
M. EL-BAZ ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Bladder Cancer ◽  
Biological Marker

552 ANTI-IL10-R1 MONOCLONAL ANTIBODY WITH CONCOMITANT BACILLUS CALMETTE-GUERIN (BCG) PREVENTS METASTATIC BLADDER CANCER IN AN IN VIVO MOUSE MODEL

2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Eric J. Askeland ◽  
Mark R. Newton ◽  
Nathan A. Bockholt ◽  
Matthew J. Knudson ◽  
Jonathan R. Henning ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Bladder Cancer ◽  
Mouse Model ◽  
Bacillus Calmette Guerin ◽  
Metastatic Bladder Cancer
Sign in / Sign up

Export Citation Format

Share Document